Treatment of Refractory ALK Rearranged Anaplastic Large Cell Lymphoma With Alectinib

First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer

Benjamin Solomon, Tony Mok, Dong‐Wan Kim et al. · New England Journal of Medicine · 2014 · 3.2K citations · Full text

Medicine, Oncology, Pharmacology +12

Alectinib versus Crizotinib in Untreated <i>ALK</i>-Positive Non–Small-Cell Lung Cancer

Solange Peters, D. Ross Camidge, Alice T. Shaw et al. · New England Journal of Medicine · 2017 · 2.5K citations · Full text

Medicine, Oncology, Pharmacology +16

Fusion of a Kinase Gene, <i>ALK</i> , to a Nucleolar Protein Gene, <i>NPM</i> , in Non-Hodgkin's Lymphoma

Stephan W. Morris, Mark N. Kirstein, Marcus B. Valentine et al. · Science · 1994 · 2.4K citations

Medicine, Genetics, Oncology +17

International Peripheral T-Cell and Natural Killer/T-Cell Lymphoma Study: Pathology Findings and Clinical Outcomes

Journal of Clinical Oncology · 2008 · 2.1K citations

Medicine, Hematology, Pathology +14

Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study

D. Ross Camidge, Yung‐Jue Bang, Eunice L. Kwak et al. · The Lancet Oncology · 2012 · 1.3K citations

Medicine, Oncology, Pharmacology +15